Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

The role of cardiac fibrosis in diastolic heart dysfunction

Show simple item record

dc.contributor.author Semionov Marius
dc.date.accessioned 2024-10-28T12:50:28Z
dc.date.accessioned 2024-11-18T20:10:38Z
dc.date.available 2024-10-28T12:50:28Z
dc.date.available 2024-11-18T20:10:38Z
dc.date.issued 2024
dc.identifier.citation Semionov Marius. The role of cardiac fibrosis in diastolic heart dysfunction. In: Abstract Book. MedEspera 2024. The 10th International Medical Congress for Students and Young Doctors. 24-27 April 2024, Chișinău, Republic of Moldova, p. 296. ISBN 978-9975-3544-2-4. en_US
dc.identifier.isbn 978-9975-3544-2-4
dc.identifier.uri https://ibn.idsi.md/collection_view/3104
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/28706
dc.description Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova en_US
dc.description.abstract Introduction. Cardiac diastolic dysfunction (DD) represents globally one of the main causes for congestive cardiac failure, occurring in 1/3 of reported cases. DD is most commonly a consequence of systemic arterial hypertension and ischemic cardiomyopathy. Histopathologic studies of hearts affected by DD have determined excessive deposits of extracellular collagen and the reconstruction of the heart architecture, known as cardiac fibrosis. The remodeling of the extracellular matrix decreases the filling rate, compliance, and diastolic suction of the heart, therefore altering cardiac function. Current discoveries suggest therapeutic potential for reversing cardiac damage. Aim of study. Emphasizing the pathophysiological and functional alterations of the fibrotic myocardium in the cardiac cycle and identifying therapeutic methods for countermanding cardiac damage. Methods and materials. Systemic analysis of up to date articles about cardiac fibrosis and diastolic dysfunction via PubMed, Google Scholar, Medscape. 14 articles (2004-2020) were chosen as the main sources. Results. The particular attribute in which cardiac fibrosis exerts modifications is the negative pressure created by the ventricle during diastole, leading to a rapid ventricular filling time, in which the collagen fibers act as an elastic system that stores energy with each contraction, consequently releasing it along with elongating the ventricle wall. From a pathophysiological outlook, the key point is the loss of energy during the distortion of the perimysial collagen, caused by the friction of internal molecules, a phenomenon called viscoelasticity. Therefore, the energy loss yields in passive stiffness and noncompliance of the ventricle wall, decreasing the diastolic suction and thus the preload of the heart. The aggregate of energy loss is directly relative to the rate between type I collagen fibers, and type III, with the latter decreasing as the fibrosis progresses. An additional factor that contributes to passive stiffness is the capacity of contraction by the fibrous tissue, independent of that of the muscle fibers, a process accomplished by the myofibroblasts. Excessive collagen synthesis has been demonstrated to be stimulated by the renin-angiotensin-aldosterone system, therefore angiotensin converting enzyme inhibitors, along with the activation of metalloproteinases may allow for reversing cardiac damage. Conclusion. Cardiac fibrosis and associated diseases can manifest in various pathogenetic ways, therefore understanding the mechanisms of diastolic dysfunction allow for a better management of affected patients. congestive cardiac failure, occurring in 1/3 of reported cases. DD is most commonly a consequence of systemic arterial hypertension and ischemic cardiomy opathy. Histopathologic studies of hearts affected by DD have determined excessive deposits of extracel lular collagen and the reconstruction of the heart architecture, known as cardi ac fibrosis. The remodeling of the extracellular matrix decreases the filling rate, complianc e, and diastolic suction of the heart, therefore altering cardiac function. Current discoveries suggest therapeutic potential for reversing cardiac damage. Aim of study. Emphasizing the pathophysiological and functional alterati ons of the fibrotic myocardium in the cardiac cycle and identifying therapeutic methods for countermanding cardiac damage. Methods and materials. Systemic analysis of up to date articles about cardiac fib rosis and diastolic dysfunction via PubMed, Google Scholar, Medscape. 14 articles (2004-2020) were chosen as the main sources. Results. The particular attribute in which cardiac fibrosis exer ts modifications is the negative pressure created by the ventricle during diastole, leading to a rapid ventricular filling time, in which the collagen fibers act as an elastic system that stores energy with each contraction, consequently releasing it along with elongating the ventricle wall. Fr om a pathophysiological outlook, the key point is the loss of energy during the distortion of the perimysial collagen, caused by the friction of internal molecules, a phenomenon called viscoelastic ity. Therefore, the energy loss yields in passive stiffness and noncompliance of the ventricle wall, decreasing the diastolic suction and thus the preload of the heart. The aggregate of energy loss is directly relative to the rate between type I collagen fibers, and type III, with the latter decreasing a s the fibrosis progresses. An additional factor that contributes to passive stiffness is the capa city of contraction by the fibrous tissue, independent of that of the muscle fibers, a process accomp lished by the myofibroblasts. Excessive collagen synthesis has been demonstrated to be stimulated by the renin-angiotensin-aldosterone system, therefore angiotensin converting enzyme inhibito rs, along with the activation of metalloproteinases may allow for reversing cardiac damage. Conclusion. Cardiac fibrosis and associated diseases can manifest i n various pathogenetic ways, therefore understanding the mechanisms of diastolic dysfun ction allow for a better management of affected patients. en_US
dc.publisher Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova en_US
dc.relation.ispartof MedEspera 2024 en_US
dc.title The role of cardiac fibrosis in diastolic heart dysfunction en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2024
    The 10th International Medical Congress for Students and Young Doctors, 24-27 April, 2024

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics